141 related articles for article (PubMed ID: 38109511)
1. [The role of PET/CT in the central nervous system tumours].
Szabó P
Magy Onkol; 2023 Dec; 67(4):321-331. PubMed ID: 38109511
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
4. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bosio G; Bertoli M; Giubbini R; Bertagna F
J Neurooncol; 2018 Feb; 136(3):577-583. PubMed ID: 29147860
[TBL] [Abstract][Full Text] [Related]
6. Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading: A Meta-analysis.
Katsanos AH; Alexiou GA; Fotopoulos AD; Jabbour P; Kyritsis AP; Sioka C
Clin Nucl Med; 2019 Nov; 44(11):864-869. PubMed ID: 31205150
[TBL] [Abstract][Full Text] [Related]
7. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
8. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies.
Mittra ES; Koglin N; Mosci C; Kumar M; Hoehne A; Keu KV; Iagaru AH; Mueller A; Berndt M; Bullich S; Friebe M; Schmitt-Willich H; Gekeler V; Fels LM; Bacher-Stier C; Moon DH; Chin FT; Stephens AW; Dinkelborg LM; Gambhir SS
PLoS One; 2016; 11(2):e0148628. PubMed ID: 26890637
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
10. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
[TBL] [Abstract][Full Text] [Related]
11. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of
He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
[TBL] [Abstract][Full Text] [Related]
13. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
[TBL] [Abstract][Full Text] [Related]
14. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
Dunet V; Pomoni A; Hottinger A; Nicod-Lalonde M; Prior JO
Neuro Oncol; 2016 Mar; 18(3):426-34. PubMed ID: 26243791
[TBL] [Abstract][Full Text] [Related]
15. Positron Emission Tomography Computed Tomography: A Guide for the General Radiologist.
Beadsmoore C; Newman D; MacIver D; Pawaroo D
Can Assoc Radiol J; 2015 Nov; 66(4):332-47. PubMed ID: 26277234
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.
Chung JK; Kim YK; Kim SK; Lee YJ; Paek S; Yeo JS; Jeong JM; Lee DS; Jung HW; Lee MC
Eur J Nucl Med Mol Imaging; 2002 Feb; 29(2):176-82. PubMed ID: 11926379
[TBL] [Abstract][Full Text] [Related]
17. [PET and malignant cerebral tumors].
Talbot JN; Kerrou K; Gault N; Gutman F; Grahek D; Touboul E; Schlienger M; Montravers F
Presse Med; 2006 Sep; 35(9 Pt 2):1347-53. PubMed ID: 16969331
[TBL] [Abstract][Full Text] [Related]
18. [Fluoroethylthyrosine 18F PET in the detection of brain tumours].
Nataf V; Kerrou K; Balogova S; Pene F; Huchet V; Gutman F; Prignon A; Muresan IP; Giannesini C; Izrael V; Schlienger M; Talbot JN
Bull Cancer; 2010 May; 97(5):495-506. PubMed ID: 20374979
[TBL] [Abstract][Full Text] [Related]
19. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
